Skip to main content
AmigoFish

Maintaining Weight Loss with Tirzepatide; the new Dyslipidemia Guidelines; Sacubitril/Valsartan & HFpEF & Functional MR; Digitoxin & Heart Failure

From Eagle's Eye View: Your Weekly CV Update From ACC.org · · 9 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

In this week's View, Dr. Eagle examines recent research into maintaining weight loss with tirzepatide. He then offers insights into the new dyslipidemia guidelines, including addressing reproductive and hormone risk factors in cardiovascular risk assessment. Next, Dr. Eagle looks at the use of sacubitril/valsartan to improve exercise tolerance in patients with heart failure with reduced ejection fraction (HFpEF) and functional mitral regurgitation (MR). Finally, Dr. Eagle summarizes a new study on the use of digitoxin and digoxin in patients with heart failure.

Subscribe to Eagle's Eye View

Back to Eagle's Eye View: Your Weekly CV Update From ACC.org · Report a problem